HERIZON-GEA-01: Zanidatamab Plus Chemotherapy ± Tislelizumab Advances First-Line Treatment in HER2-Positive Gastroesophageal Adenocarcinoma
HERIZON-GEA-01 is a pivotal phase III trial evaluating zanidatamab-based regimens, with or without the PD-1 inhibitor tislelizumab, compared with trastuzumab plus standard chemotherapy in patients...
